WALTHAM, Mass.--(BUSINESS WIRE)--Oscient Pharmaceuticals Corporation’s (Nasdaq: OSCI) commercialization partner for FACTIVE® (gemifloxacin mesylate) tablets, Menarini Group, a leading European pharmaceutical company based in Italy, has submitted a regulatory filing seeking approval of FACTIVE in Europe. Menarini, with broad sales and marketing coverage throughout Europe and expertise in research and clinical development, has the fourth largest pharmaceutical sales force in Europe and is second largest in terms of calls to primary care physicians.
